ALDH1-Modified Stem Cells for Non-Myeloablative Bone Marrow Reconstitution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional myeloablative bone marrow transplants cause severe side effects and prolonged susceptibility to infections due to the destruction of healthy immune and stem cells, necessitating a need for non-myeloablative methods that minimize toxicity and promote rapid recovery.
Innovation Solution
The use of cyclophosphamide-resistant modified bone marrow stem cells, expressing ALDH1 and administered at non-myeloablative doses, along with a non-myeloablative chemotherapy regimen, to perform bone marrow transplants without causing myeloablation, thereby reducing side effects and maintaining immune function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If myeloablative chemotherapy is used to kill unhealthy bone marrow cells, then the unhealthy cells are eliminated, but healthy immune and stem cells are also destroyed causing severe side effects and prolonged infection susceptibility
Solution Approach 1:
The patent segments the bone marrow cell population by engineering stem cells to express a selectable marker (e.g., GFP) that distinguishes them from endogenous cells. This allows selective targeting and elimination only of the engineered unhealthy cells through chemotherapy or radiation, while preserving healthy endogenous bone marrow cells, thereby eliminating the need for myeloablation and its associated side effects
Solution Approach 2:
The patent uses a selectable marker (such as GFP or other reporter genes) as an intermediary to tag engineered bone marrow stem cells. This marker serves as a target for selective chemotherapy or radiation, enabling precise elimination of unhealthy engineered cells without affecting healthy endogenous cells, thus resolving the contradiction between eliminating unhealthy cells and preserving healthy ones
2Reliability
If high doses of chemotherapy and radiation are administered to achieve bone marrow reconstitution, then unhealthy cells are killed, but the patient becomes highly susceptible to infections requiring prolonged hospital proximity and antibiotic treatment
Solution Approach 1:
The patent performs preliminary action by engineering bone marrow stem cells ex vivo with selectable markers and desired therapeutic modifications before transplantation. This pre-engineering allows for selective elimination of only the engineered cells later, avoiding the need for prolonged myeloablation and enabling faster recovery, thus reducing the loss of time while maintaining reconstitution reliability
3Object-affected harmful factors
If myeloablative chemotherapy is used to treat bone marrow diseases, then diseased cells are eliminated, but acute toxicities and long-term side effects such as cataracts, growth retardation, and cardiotoxicity occur
Solution Approach 1:
The patent converts the potential harm of chemotherapy into a benefit by using it selectively only against engineered unhealthy cells that express the selectable marker. Healthy endogenous cells remain untouched, transforming the harmful myeloablative approach into a selective therapy that eliminates diseased cells without causing acute toxicities or long-term side effects
Solution Approach 2:
The selectable marker acts as an intermediary that enables selective targeting of unhealthy engineered cells. By attaching the therapeutic payload (chemotherapy sensitivity) only to cells expressing the marker, the patent eliminates diseased cells while sparing healthy tissue, thereby converting a harmful general cytotoxic approach into a beneficial selective therapy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for effective bone marrow reconstitution with minimal toxicity, reducing the risk of infections and shortening recovery time, while maintaining immune competence in patients.
Implementation Method 1
cells expressing a heterologous gene encoding aldehyde dehydrogenase 1 (ALDH1)
Implementation Method 2
aldehyde dehydrogenase 1 (ALDH1)
Data Source
Figure 1
Figure 2A
Figure 2B
AI summary
The disclosure relates generally to methods and compositions for performing bone marrow transplants using a non-myeloablative chemotherapeutic agent and chemotherapeutic-resistant cells. Using the methods and compositions described herein, a patient's bone marrow may be reconstituted and the patient avoids adverse side effects, including myeloablation and/or an impaired immune system.